MX2020013169A - Conjugados de camptotecina. - Google Patents
Conjugados de camptotecina.Info
- Publication number
- MX2020013169A MX2020013169A MX2020013169A MX2020013169A MX2020013169A MX 2020013169 A MX2020013169 A MX 2020013169A MX 2020013169 A MX2020013169 A MX 2020013169A MX 2020013169 A MX2020013169 A MX 2020013169A MX 2020013169 A MX2020013169 A MX 2020013169A
- Authority
- MX
- Mexico
- Prior art keywords
- camptothecin conjugates
- camptothecin
- conjugates
- preparations
- methods
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title 1
- 229940127093 camptothecin Drugs 0.000 title 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Abstract
Se describen conjugados de anticuerpos con compuestos de camptotecina, con métodos de uso y preparaciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862681847P | 2018-06-07 | 2018-06-07 | |
US201862777491P | 2018-12-10 | 2018-12-10 | |
PCT/US2019/035971 WO2019236954A1 (en) | 2018-06-07 | 2019-06-07 | Camptothecin conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013169A true MX2020013169A (es) | 2021-03-29 |
Family
ID=67139801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013169A MX2020013169A (es) | 2018-06-07 | 2019-06-07 | Conjugados de camptotecina. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230036256A1 (es) |
EP (1) | EP3801633A1 (es) |
JP (2) | JP2021527040A (es) |
KR (1) | KR20210053871A (es) |
CN (1) | CN112512592A (es) |
AU (1) | AU2019282767A1 (es) |
BR (1) | BR112020024915A2 (es) |
CA (1) | CA3101866A1 (es) |
IL (1) | IL278990B1 (es) |
MX (1) | MX2020013169A (es) |
SG (1) | SG11202011915TA (es) |
TW (1) | TW202015740A (es) |
WO (1) | WO2019236954A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190343828A1 (en) * | 2018-04-06 | 2019-11-14 | Seattle Genetics, Inc. | Camptothecin peptide conjugates |
PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
CR20220057A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
CN114929284A (zh) * | 2019-10-04 | 2022-08-19 | 西根公司 | 喜树碱肽缀合物 |
WO2021067820A1 (en) * | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
CN116390770A (zh) * | 2020-05-13 | 2023-07-04 | 思进股份有限公司 | 使用抗cd30抗体-药物缀合物的组合治疗癌症的方法 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
AU2022330892A1 (en) * | 2021-08-19 | 2024-03-21 | Simcere Zaiming Pharmaceutical Co., Ltd. | Camptothecin derivative, and pharmaceutical composition and use thereof |
WO2023083919A1 (en) | 2021-11-09 | 2023-05-19 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a camptothecin moiety |
WO2023083900A1 (en) | 2021-11-09 | 2023-05-19 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a drug moiety |
WO2023125530A1 (en) * | 2021-12-28 | 2023-07-06 | Beigene, Ltd. | Antibody drug conjugates |
WO2023172968A1 (en) * | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023178289A2 (en) * | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
WO2023180485A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
WO2023180484A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing ptk7 |
WO2023180490A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
WO2023204631A1 (ko) * | 2022-04-20 | 2023-10-26 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
WO2023217227A1 (zh) * | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
WO2024006272A1 (en) * | 2022-06-27 | 2024-01-04 | Sutro Biopharma, Inc. | β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF |
WO2024059236A1 (en) * | 2022-09-15 | 2024-03-21 | Adcentrx Therapeutics Inc. | Novel camptothecin analogs and immunoconjugates thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
CA2262994A1 (en) | 1996-08-02 | 1998-02-12 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
ITMI20041427A1 (it) | 2004-07-15 | 2004-10-15 | Univ Degli Studi Milano | Sintesi di molecole organometalliche utilizzabili come marcatori di sostanze organiche |
KR102433686B1 (ko) | 2012-05-15 | 2022-08-19 | 씨젠 인크. | 자가-안정화 링커 접합체 |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
CN105813653B (zh) * | 2013-12-19 | 2020-06-26 | 西雅图基因公司 | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 |
BR112017012377A2 (pt) * | 2014-12-09 | 2018-04-24 | Abbvie Inc | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula |
JP2018502839A (ja) * | 2014-12-09 | 2018-02-01 | アッヴィ・インコーポレイテッド | Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート |
AU2017237186A1 (en) | 2016-03-25 | 2018-11-01 | Seagen Inc. | Process for the preparation of PEGylated drug-linkers and intermediates thereof |
JP7244987B2 (ja) * | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
WO2023178289A2 (en) * | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
-
2019
- 2019-06-06 TW TW108119649A patent/TW202015740A/zh unknown
- 2019-06-07 CA CA3101866A patent/CA3101866A1/en active Pending
- 2019-06-07 SG SG11202011915TA patent/SG11202011915TA/en unknown
- 2019-06-07 JP JP2020567763A patent/JP2021527040A/ja active Pending
- 2019-06-07 MX MX2020013169A patent/MX2020013169A/es unknown
- 2019-06-07 KR KR1020217000418A patent/KR20210053871A/ko unknown
- 2019-06-07 IL IL278990A patent/IL278990B1/en unknown
- 2019-06-07 AU AU2019282767A patent/AU2019282767A1/en active Pending
- 2019-06-07 EP EP19735436.8A patent/EP3801633A1/en active Pending
- 2019-06-07 WO PCT/US2019/035971 patent/WO2019236954A1/en unknown
- 2019-06-07 CN CN201980050566.6A patent/CN112512592A/zh active Pending
- 2019-06-07 BR BR112020024915-7A patent/BR112020024915A2/pt unknown
- 2019-06-07 US US16/972,469 patent/US20230036256A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205217A patent/JP2024023543A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202015740A (zh) | 2020-05-01 |
CN112512592A (zh) | 2021-03-16 |
IL278990A (en) | 2021-01-31 |
IL278990B1 (en) | 2024-04-01 |
EP3801633A1 (en) | 2021-04-14 |
AU2019282767A1 (en) | 2021-01-07 |
JP2021527040A (ja) | 2021-10-11 |
SG11202011915TA (en) | 2020-12-30 |
JP2024023543A (ja) | 2024-02-21 |
WO2019236954A1 (en) | 2019-12-12 |
BR112020024915A2 (pt) | 2021-03-09 |
KR20210053871A (ko) | 2021-05-12 |
CA3101866A1 (en) | 2019-12-12 |
US20230036256A1 (en) | 2023-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013169A (es) | Conjugados de camptotecina. | |
MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
PH12018501589A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
WO2018109174A3 (en) | Il-11 antibodies | |
PH12017501780A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
WO2018109170A3 (en) | Il-11ra antibodies | |
PH12016501680B1 (en) | Anti-egfrviii antibodies and uses thereof | |
PH12018501153A1 (en) | Novel anti-claudin antibodies and methods of use | |
WO2018081648A8 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2016013857A (es) | Anticuerpos anti-rnf43 novedosos y metodos de uso. | |
MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018010491A (es) | Proceso para la preparacion de un conjugado anticuerpo-rifamicina. | |
MX2022003212A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso. | |
MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
PH12020552159A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
MX2022001731A (es) | Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12. |